Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 7/20 | 0.38 |
| ▸ | ATM | Q13315 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 5/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563661 | 0.93 | PDE4D (0.35) | PDE4DATMKCNH2PIK3CAMTOR | |
| SCHEMBL564303 | 0.92 | GCK (0.39) | PDE4DATMKCNH2PIK3CAMTOR | |
| SCHEMBL564288 | 0.92 | PDE4D (0.34) | PDE4DATMKCNH2PIK3CAMTOR | |
| SCHEMBL563584 | 0.90 | KDM4E (0.40) | PDE4DATMGCKPDE4APDE4B | |
| SCHEMBL564631 | 0.89 | GCK (0.35) | PDE4DPIK3CAGCKPDE4APDE4B | |
| SCHEMBL1076403 | 0.86 | IDO1 (0.39) | ATMKCNH2GCKMAPTSCN9A | |
| SCHEMBL564327 | 0.85 | APP (0.32) | PDE4DPIK3CAGCKPDE4APDE4B | |
| SCHEMBL564358 | 0.84 | GCK (0.38) | PDE4DPIK3CAGCKFGFR1FGFR2 | |
| SCHEMBL564680 | 0.83 | KDM4E (0.37) | PDE4DATMGCKPDE4APDE4B | |
| SCHEMBL564516 | 0.82 | GCK (0.34) | PDE4DATMKCNH2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | PDE4D 1302/4885ATM 2440/4885KCNH2 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.